Kotak Mutual Fund increased its stake in Zydus Lifesciences from 1.13% to 1.19%, raising its shareholding from 1,13,97,485 to 1,19,11,788 shares.
A vertically integrated pharmaceutical company, Zydus Lifesciences develops, manufactures, and markets generic drugs, specialty pharmaceuticals, and biologics for domestic and international markets. The company operates across multiple therapeutic areas including cardiology, gastroenterology, oncology, and immunology. It serves patients globally through its extensive distribution network, research capabilities, and commitment to addressing unmet healthcare needs across diverse populations and geographies.
Wholly owned subsidiary of Kotak Mahindra Bank, one of India's leading private banks. Manages over Rs 4.5 lakh crore in AUM. MD Nilesh Shah is a fixture in Indian financial media and one of the most quoted fund managers in the country. Known for disciplined quality growth positioning and clear communication of investment rationale to investors.
